Brachytherapy
Volume 7, Issue 1 , Pages 43-46 , January 2008

Systemic iodine 125 activity after GliaSite brachytherapy: Safety considerations

  • Jarrod B. Adkison

      Affiliations

    • Department of Human Oncology, University of Wisconsin, School of Medicine and Public Health, Madison, WI
    • ,
  • Bruce Thomadsen

      Affiliations

    • Department of Human Oncology, University of Wisconsin, School of Medicine and Public Health, Madison, WI
    • Department of Medical Physics, University of Wisconsin, School of Medicine and Public Health, Madison, WI
    • ,
  • Steven P. Howard

      Affiliations

    • Department of Human Oncology, University of Wisconsin, School of Medicine and Public Health, Madison, WI
    • Corresponding Author InformationCorresponding author. Department of Human Oncology, University of Wisconsin, School of Medicine and Public Health, K4/350 CSC, 600 Highland Avenue, Madison, WI 53792. Tel.: +1-608-263-9961; fax: +1-608-263-9167.

Received 2 August 2007 ,Revised 5 November 2007 ,Accepted 19 November 2007.

References 

  1. Chan TA, Weingart JD, Parisi M, et al. Treatment of recurrent glioblastoma multiforme with GliaSite brachytherapy. Int J Radiat Oncol Biol Phys. 2005;62:1133–1139
  2. Brem H, Piantadosi S, Burger PC, et al. Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The Polymer-brain Tumor Treatment Group. Lancet. 1995;345:1008–1012
  3. Rogers LR, Rock JP, Sills AK, et al. Results of a phase II trial of the GliaSite radiation therapy system for the treatment of newly diagnosed, resected single brain metastases. J Neurosurg. 2006;105:375–384
  4. Patchell RA, Tibbs PA, Regine WF, et al. Postoperative radiotherapy in the treatment of single metastases to the brain: A randomized trial. JAMA. 1998;280:1485–1489
  5. Stubbs JB, Strickland AD, Frank RK, et al. Biodistribution and dosimetry of an aqueous solution containing sodium 3-(125I)iodo-4-hydroxybenzenesulfonate (Iotrex) for brachytherapy of resected malignant brain tumors. Cancer Biother Radiopharm. 2000;15:645–656
  6. deGuzman AF, Kearns WT, Shaw E, et al. Radiation safety issues with high activities of liquid I-125: Techniques and experience. J Appl Clin Med Phys. 2003;4:143–148
  7. Strzelczyk J, Safadi R. Radiation safety considerations in GliaSite 125I brain implant procedures. Health Phys. 2004;86:S120–S123
  8. Tatter SB, Shaw EG, Rosenblum ML, et al. An inflatable balloon catheter and liquid 125I radiation source (GliaSite Radiation Therapy System) for treatment of recurrent malignant glioma: Multicenter safety and feasibility trial. J Neurosurg. 2003;99:297–303
  9. Noble JM, Canoll P, Honig LS. Brain tumor-associated dementia. Sci Aging Knowledge Environ. 2005;2005:dn2
  10. Duffau H, Capelle L. Incontinence after brain glioma surgery: New insights into the cortical control of micturition and continence. Case report. J Neurosurg. 2005;102:148–151

PII: S1538-4721(07)00277-2

doi: 10.1016/j.brachy.2007.11.001

Brachytherapy
Volume 7, Issue 1 , Pages 43-46 , January 2008

Article Tools